Genomic sequencing has become the central engine of modern precision medicine. Next-generation sequencing (NGS) technologies are transforming oncology, rare disease diagnostics, and infectious disease surveillance by enabling the simultaneous analysis of thousands of genetic variants. Landmark initiatives such as the Human Microbiome Project1 demonstrated the links between human and microbial genomes, paving the way for innovative diagnostics and targeted therapeutics. Yet, as these technologies advance, they must operate within evolving regulatory frameworks. In Europe, the In Vitro Diagnostic Regulation (IVDR) represents both challenge and opportunity as it seeks to ensure patient safety and quality while striving not to stifle innovation.
This article explores how NGS devices can align with IVDR principles, highlighting the unique complexities they pose while offering strategies for manufacturers, laboratories, and partners to successfully navigate this landscape.
NGS Across the Diagnostic Landscape
NGS has become indispensable in clinical practice. For instance, oncology is rich in comprehensive tumour profiling guides, targeted therapies and immuno-oncology strategies. Likewise, in rare disease diagnostics, whole-exome and whole-genome sequencing uncover elusive genetic causes in small patient populations. Additionally, infectious disease sequencing, from COVID-19 to antimicrobial resistance monitoring, supports outbreak tracing and pandemic preparedness. All in all, the promise of NGS data is clear: deeper, faster, and more actionable insights. But with this promise comes greater regulatory responsibility.
The Responsibility of IVD Regulatory Alignment
The IVDR introduces a more stringent framework for in vitro diagnostics, emphasizing risk-based classification, robust performance evaluation, and continuous post-market surveillance. For NGS, this alignment requires particular attention. Unlike traditional IVDs, NGS assays generate highly multiplexed genomic outputs and rely on continuously evolving workflows that span pre-analytical steps, wet-lab processes and bioinformatics interpretation.
Establishing clinical evidence is especially challenging when variant prevalence is low, and post market surveillance must account for the dynamic nature of genomic knowledge bases, where variant classifications and clinical significance evolve over time. Together, these factors stretch the boundaries of traditional regulatory models and require a more nuanced approach to conformity assessment.
As the world’s first National Standards Body, we are deeply knowledgeable with NGS sequencing, genomic knowledge bases and the complex interplay between evolving scientific innovation, clinical safety requirements and IVD regulatory frameworks. Our deep understanding of NGS technologies and genomic data enables us to conduct conformity assessments that fully account for analytical, bioinformatics, and regulatory complexities, helping manufacturers navigate IVDR expectations with clarity.
Regulatory Demands of NGS: The Reality
Establishing clinical evidence in accordance with Annex XIII of the IVDR can be particularly complex for next generation sequencing (NGS) devices, especially because evidence generation for rare variants is inherently challenging when patient numbers are limited. This complexity is heightened when the intended purpose spans multiple tumour types, where biological heterogeneity and tissue specific differences in variant prevalence make both analytical validation and clinical performance justification more demanding. Furthermore, reproducibility across laboratories and sequencing platforms remains a pressing concern, driven by the inherent complexity of NGS workflows that involve multiple interdependent steps. Variability in pre analytical processing, library preparation, enrichment methods, sequencing chemistry, and downstream bioinformatics algorithms can all influence variant detection performance, making reproducibility a key challenge to demonstrate under the IVDR. Post market monitoring must also be factored into the equation, as variant classifications can change over time, forcing laboratories and manufacturers to adapt their reporting while maintaining compliance. In certain cases, such reclassification can also have regulatory implications for the device itself—for example, when a variant becomes determinative for eligibility to a targeted therapy in specific tissue types, potentially bringing the device within the scope of a companion diagnostic and thereby triggering a different Annex VIII classification and conformity assessment route under the IVDR.
NGS Real-World Applications
Across oncology, rare disease, and infectious disease, NGS demonstrates its promise while also highlighting important regulatory considerations in real-world applications:
- Oncology NGS Applications
NGS has become a cornerstone of modern oncology, generating genomic information that can support or determine diagnosis, prognosis, therapy selection and management, disease monitoring, risk assessment, and cancer screening. Diagnostic applications may include identification of driver fusions or defining tumour type through genomic signatures; prognostic information may be derived from mutations associated with disease aggressiveness; therapy selection is guided by actionable biomarkers linked to targeted therapies or immuno‑oncology agents; disease monitoring can be enabled through serial sequencing for molecular residual disease; hereditary cancer risk can be assessed through the detection of germline variants such as BRCA1/2; and early cancer screening applications may leverage circulating‑tumour DNA–based NGS assays. Under the IVDR, Annex XIII provides the framework: manufacturers are required to demonstrate scientific validity (Section 1.2.1), analytical performance (Section 1.2.2), and clinical performance (Section 1.2.3) in alignment with the device’s intended purpose. For assays addressing a broad range of analytes and clinical conditions, a well‑reasoned evidence strategy—explicitly scoping claims and justifying data sources—is necessary. - Genetic Diseases
For genetic diseases, NGS offers unparalleled potential to uncover elusive causes—ranging from whole‑exome and whole‑genome sequencing for rare monogenic disorders to high‑volume reproductive genetics applications such as non‑invasive prenatal testing (NIPT). The core challenge is evidence: rare and low‑prevalence conditions limit the size of clinical datasets, while screening contexts like NIPT require performance estimates that reflect both prevalence subgroup characteristics spanning subgroups such as gestational age, foetal fraction and pregnancy type, spanning singleton, twin, and other multifetal pregnancies. - Infectious Disease Sequencing
NGS has proven indispensable in infectious disease management, from tracing COVID 19 outbreaks to monitoring antimicrobial resistance. The technology enables rapid identification of pathogens and their variants, supporting public health decision making in real time. However, the urgency of outbreak response often collides with the structured validation demanded by IVDR. During the pandemic, laboratories had to deploy sequencing at speed, even as regulatory frameworks required evidence of accuracy, reproducibility, and utility. This tension illustrates the broader challenge of aligning public health imperatives with compliance obligations. Going forward, infectious disease sequencing will continue to test the flexibility of regulatory systems, demanding pathways that accommodate both rapid response and patient safety.
Practical Strategies for Alignment
To navigate the IVDR successfully, manufacturers and laboratories must adopt practical, evidence‑driven strategies that align with Annex XIII requirements. A modular approach to validation, separating platform performance, pre-analytics, library preparation, sequencing chemistry, and bioinformatics pipeline verification and validation from assay‑specific claims, can streamline evidence generation while ensuring that each component is appropriately demonstrated. Bioinformatics validation is increasingly recognised as an essential element of performance evaluation, requiring the same level of rigour as wet‑lab processes, including verification, validation, version control, and justification of reference datasets. Finally, early regulatory engagement, including clarification of intended purpose and performance evaluation strategy, can help ensure alignment with IVDR expectations while maintaining the independence of the conformity assessment process.
Future Pathways for NGS-based IVDs
NGS is central to the future of diagnostics and precision medicine. The IVDR provides a framework that, if interpreted with balance, can safeguard patients while enabling innovation. Manufacturers, laboratories, and partners therefore must embrace strategies that align cutting-edge science with regulatory principles. By fostering collaboration, transparency, and dialogue, the wider genomics ecosystem can help shape workable pathways under the IVDR. The goal is clear: ensure that patients benefit from the most advanced technologies without compromising safety or trust. Ultimately the aim is to ensure that scientific progress and regulatory expectations remain aligned, enabling NGS technologies to evolve responsibly within a framework that supports quality, reliability, and confidence.
